Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$11.3 million.

  • Cardiff Oncology's Income towards Parent Company rose 507.59% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.4 million, marking a year-over-year decrease of 1745.82%. This contributed to the annual value of -$45.4 million for FY2024, which is 979.37% down from last year.
  • As of Q3 2025, Cardiff Oncology's Income towards Parent Company stood at -$11.3 million, which was up 507.59% from -$13.9 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Income towards Parent Company peaked at -$5.4 million during Q1 2021, and registered a low of -$13.9 million during Q2 2025.
  • For the 5-year period, Cardiff Oncology's Income towards Parent Company averaged around -$10.3 million, with its median value being -$10.4 million (2022).
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 10349.14% in 2022, then soared by 1696.81% in 2024.
  • Cardiff Oncology's Income towards Parent Company (Quarter) stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then grew by 0.72% to -$9.3 million in 2023, then dropped by 26.39% to -$11.8 million in 2024, then grew by 4.47% to -$11.3 million in 2025.
  • Its last three reported values are -$11.3 million in Q3 2025, -$13.9 million for Q2 2025, and -$13.4 million during Q1 2025.